A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 2, 2011, Pages 315-324

  Kanai, Fumihiko ^a,b,g   Yoshida, Haruhiko ^a   Tateishi, Ryosuke ^a   Sato, Shinpei ^a   Kawabe, Takao ^a   Obi, Shuntaro ^c   Kondo, Yuji ^d   Taniguchi, Makoto ^d   Tagawa, Kazumi ^d   Ikeda, Masafumi ^e   Morizane, Chigusa ^e   Okusaka, Takuji ^e   Arioka, Hitoshi ^f   Shiina, Shuichiro ^a   Omata, Masao ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c Kyoundo Hospital   (Japan)

^d MITSUI MEMORIAL HOSPITAL   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL   (Japan)

^f YOKOHAMA ROSAI HOSPITAL   (Japan)

^g CHIBA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Advanced HCC; Angiogenesis; Liver function; Pharmacokinetics; Tolerability; TSU 68

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; BLOOD CLOTTING FACTOR 8; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERLEUKIN 8; PLATELET DERIVED GROWTH FACTOR; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; 5 ((1,2 DIHYDRO 2 OXO 3H INDOL 3 YLIDENE)METHYL) 2,4 DIMETHYL 1H PYRROLE 3 PROPANOIC ACID; 5-((1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE)METHYL)-2,4-DIMETHYL-1H-PYRROLE-3-PROPANOIC ACID; ANGIOGENESIS INHIBITOR; ANGIOGENESIS MODULATOR; BIOLOGICAL MARKER; INDOLE DERIVATIVE; PROPIONIC ACID DERIVATIVE;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ADULT; ADVANCED CANCER; AGED; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASCITES; BLOOD SAMPLING; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ERYTHROPENIA; FEMALE; HEMATOCRIT; HUMAN; HYPOALBUMINEMIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION TEST; LIVER METASTASIS; MALAISE; MALE; MAXIMUM PLASMA CONCENTRATION; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; LIVER TUMOR; MIDDLE AGED; NECROSIS; ORAL DRUG ADMINISTRATION; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANGIOGENESIS INHIBITORS; ANGIOGENESIS MODULATING AGENTS; AREA UNDER CURVE; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; INDOLES; LIVER NEOPLASMS; MALE; MIDDLE AGED; NECROSIS; PROPIONIC ACIDS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VASCULAR CELL ADHESION MOLECULE-1;

EID: 79953803472     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1320-2     Document Type: Article

References (32)

1. Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108 (Pubitemid 40372904)
2. Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42:1208-1236 (Pubitemid 43112690)
3. Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390
4. Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25-34
5. Laird AD, Vajkoczy P, Shawver LK et al (2000) SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 60:4152-4160 (Pubitemid 30636598)
6. Naumova E, Ubezio P, Garofalo A et al (2006) The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis. Clin Cancer Res 12:1839-1849
7. Yorozuya K, Kubota T, Watanabe M et al (2005) TSU-68 (SU6668) inhibits local tumor growth and liver metastasis of human colon cancer xenografts via anti-angiogenesis. Oncol Rep 14:677-682
8. Solorzano CC, Jung YD, Bucana CD et al (2001) In vivo intracellular signaling as a marker of antiangiogenetic activity. Cancer Res 61:7048-7051 (Pubitemid 32946494)
9. Kuenen BC, Giaccone G, Ruijter R et al (2005) Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies. Clin Cancer Res 11:6240-6246 (Pubitemid 41262954)
10. Kanai F, Yoshida H, Teratani T et al (2006) New feasibility study design with hepatocellular carcinoma: a phase I/II study of TSU-68, an oral angiogenesis inhibitor [Abstract]. J Clin Oncol 24 (Suppl): 213S
11. Kanai F, Yoshida H, Tateishi R et al (2008) Final results of a phase I/II trial of the oral anti-angiogenesis inhibitor TSU-68 in patients with advanced hepatocellular carcinoma [Abstract]. J Clin Oncol 26 (Suppl): 235S
12. Kitamura R, Yamamoto Y, Nagayama S et al (2007) Decrease in plasma concentrations of antiangiogenic agent TSU-68 ((Z)-5-[(1,2-dihydro-2-oxo-3H- indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-propanoic acid) during oral administration twice a day to rats. Drug Metab Dispos 35:1611-1616 (Pubitemid 47296055)
13. Kitamura R, Asanoma H, Nagayama S et al (2008) Identification of human liver cytochrome P450 isoforms involved in autoinduced metabolism of the antiangiogenic agent (Z)-5-[(1, 2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2, 4-dimethyl-1H-pyrrole-3-propanoic acid (TSU-68). Drug Metab Dispos 36:1003-1009 (Pubitemid 351717456)
14. Ueda Y, Shimoyama T, Murakami H et al (2010) Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals with solid tumors (under submission)
15. Murakami H, Ueda Y, Shimoyama T et al. (2010) Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple tyrosine kinase inhibitor, administered after meals with solid tumors (under submission)
16. Green H, Benedetti J, Crowley J (2002) Clinical trials in oncology, 2nd edn. Chapman & Hall, London
17. Fleming TR (1982) One-sample multiple testing procedures for phase II clinical trials. Biometrics 38:143-151
18. The Liver Cancer Study Group of Japan (2000) The general rules for the clinical and pathological study of primary liver cancer. Version 4. Kanehara & Co., Ltd., Tokyo
19. Makuuchi M, Belghiti J, Belli G et al (2003) IHPA concordant classification of primary liver cancer: working group report. J Hepatobiliary Pancreat Surg 10:26-30 (Pubitemid 36850300)
20. Llovet JM, Bruix J (2008) Novel advancements in the management of hepatocellular carcinoma 2008. J Hepatol 48: S20-S37
21. Roodhart JM, Langenberg MH, Witteveen e et al (2008) The molecular basis of class side effects due to treatment with inhibitors of VEGF/VEGFR pathway. Curr Clin Pharmacol 3:132-143
22. Faivre S, Raymond E, Boucher e et al (2009) Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 10:794-800
23. Llovet JM, Di Bisceglie AM, Bruix J et al (2008) Panel of experts in HCC-design clinical trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100:698-711
24. Furuse J, Ishii H, Nakachi K et al (2008) Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 99:159-165 (Pubitemid 350239045)
25. Zhu AX, Sahani DV, Duda DG et al (2009) Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 27:3027-3035
26. Thomas MB, Abbruzzese JL (2005) Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol 23:8093-8108 (Pubitemid 46657412)
27. Pang R, Poon RT (2006) Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett 242:151-167 (Pubitemid 44485315)
28. Poon RT, Lau C, Pang R et al (2007) High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies. Ann Surg Oncol 14:1835-1845 (Pubitemid 46870942)
29. Alexiou D, Karayiannakis AJ, Syrigos KN et al (2001) Serum levels of E-selectin, ICAM-1, and VCAM-1 in colorectal cancer patients: correlations with clinicopathological features, patient survival and tumor surgery. Eur J Cancer 37:2392-2397 (Pubitemid 33097476)
30. Alexiou D, Karayiannakis AJ, Syrigos KN et al (2003) Clinical significance of serum levels of E-selectin, intracellular adhesion molecule-1, and vascular cell adhesion molecule-1 in gastric cancer patients. Am J Gastroenterol 98:478-485 (Pubitemid 36232403)
31. O'Hanlon DM, Fitzsimons H, Lynch J et al (2002) Soluble adhesion molecule (E-selectin, ICAM-1 and VCAM-1) in breast carcinoma. Eur J Cancer 38:2252-2257 (Pubitemid 35346466)
32. Joanna WH, Ronnie TP, Cindy ST et al (2004) Clinical significance of serum vascular cell adhesion molecule-1 levels in patients with hepatocellular carcinoma. World J Gastroenterol 10:2014-2018